Background. Several promising human immunodeficiency virus (HIV) treatment adherence interventions have been identified, but data about their cost-effectiveness are lacking. This study examines the trial-based cost-effectiveness and cost-utility of the proven-effective Adherence Improving Self-Management Strategy (AIMS), from a societal perspective, with a 15-month time horizon.
was effective in reducing viral load and treatment failure [28, 29] . A Markov model evaluating the cost-effectiveness of AIMS with a 10-year and lifetime horizon suggested that AIMS is cost-effective and even cost-saving [28] . It is important, however, to combine results from model-based economic evaluations with trial-based economic evaluations, which maintain the integrity of randomization and make no assumptions about data beyond the observation period. The present study reports on the trial-based economic evaluation, piggy-backed on the multicenter trial, examining the cost-effectiveness and cost-utility of AIMS compared to treatment as usual (TAU) over the 15-month trial follow-up period.
METHODS
The study protocol has been published elsewhere [30] and is registered online on ClinicalTrials.gov (identifier: NCT01429142). The risk of bias justification table (RATIONALE) Table has been used to describe in detail the strategies utilized for reducing the risk of bias [31] . The effectiveness paper including a Markov economic model is published elsewhere [29] .
Study Design and Patient Recruitment
Patients were recruited by 21 HIV nurses from 7 Dutch HIV clinics from June 2011 to March 2013, with an average follow-up of 14.5 months. Treatment-naive and treatment-experienced patients at risk for viral rebound (ie, a recent detectable viral load and suboptimal adherence) were eligible for participation [30] . Patients were randomized to AIMS or TAU, using block randomization to balance intervention and control patients within nurses. The randomization procedure was stratified for treatment experience. Please see above-mentioned sources for further details [30, 31] . Written informed consent was obtained from each patient. The study was approved by the ethics committee of each participating center.
Treatment as Usual
TAU adherence support was comprised of 1-on-1 nurse-support of medium to high standard compared with meta-analyses on this topic [26, 32, 33] . Nurses routinely delivered tailored information and medication intake instructions, provided feedback on clinical outcomes, encouraged adherence, developed individually tailored medication plans with reminders, offered dose organizers and reminder devices/text messaging services, explored social support, and discussed adherence problems and solutions.
Intervention
AIMS is a nurse-delivered intervention designed to fit in routine clinical care, and employs educational, motivational, action planning, and self-management techniques. An important element is the measurement of medication intake with an electronic medication monitor (MEMS, AARDEX Corporation). These data are discussed with patients to identify causes of and tailored solutions for suboptimal adherence [2, 27, 30] . Nurses were trained in AIMS for approximately 18 hours. In this trial, patients were expected to receive the intervention at least 3 times: at baseline and around month 5 and 10.
Sample Size
A sample of 230 randomized patients was required to obtain 80% power to detect a significant intervention effect on viral load for at least 1 of 3 time points with α = .05 (2-sided), using a Bonferroni correction and assuming a maximum dropout of 10% [30] .
Identification, Measurement, and Valuation of Costs
The cost-effectiveness and cost-utility analyses were conducted from a societal perspective [34] . The following cost components were measured: direct costs (eg, intervention costs and other healthcare costs) and indirect costs (eg, informal care costs, productivity losses).
Medical records were used to collect information on all healthcare consumed in the hospital where patients also attended the HIV clinic. Paper-and-pencil questionnaires were used to assess all other healthcare consumption (eg, visits to the general practitioner) and the indirect costs.
Treatment-experienced patients were asked to complete the questionnaires during 4 planned study visits: at baseline and around months 5, 10, and 15. Treatment-naive patients completed 5 questionnaires, as they visit the clinic more frequently during the initial stages of treatment (at baseline and around months 3, 6, 10, and 15). The recall period was standardized at 4 months for the baseline and last follow-up questionnaires. The recall period for the intermediate questionnaires was allowed to vary, as questionnaires were handed over during clinic visits and intervisit intervals can vary between patients. For the baseline and follow-up questionnaires, HIV nurses reminded patients to complete the questionnaire if it was not returned within 1 week. This was not done for the intermediate questionnaires purposely, as additional nurse-patient contacts were deemed to possibly interfere with adherence behavior.
Analyses were performed according to the Dutch manual for cost analysis in healthcare research [35] . Medication costs were calculated using prices based on daily defined dosage (see www.medicijnkosten.nl). Prices of informal care, absence of school, and domestic activities were based on the Dutch minimum wage [35] . Productivity losses were calculated according to the friction cost method, based on the mean income of the Dutch population by age and gender [35] . Costs were expressed in euros and converted to the price year 2013. Discounting was considered unnecessary given the 15-month follow-up period.
Identification, Measurement, and Valuation of Effects
The primary outcome measure for the cost-effectiveness analysis was the log 10 plasma viral load. An additional and clinically more meaningful outcome measure was treatment failure, defined as a detectable viral load at 2 consecutive measures (± 5-month intervals).
The outcome measure for the cost-utility analysis was utilities converted to quality-adjusted life-years (QALYs). Utilities were measured using the Short-Form Health Survey version 2 [36, 37] , to allow for comparison of our results with economic evaluations conducted in other conditions [34] . QALYs were calculated by means of the "under the curve method, " in which the time in a certain health state was multiplied by the utility of this health state [31] .
Analyses
All analyses were performed based on intention to treat. Missing questionnaire data met missing at random assumptions, as missing values were unrelated to demographics, plasma viral load, utilities, healthcare consumption components, or group assignment. Missing data were imputed using expectation maximization (for details on data imputation, see Supplementary Appendix 1).
As in the effectiveness analyses [29] , it was planned a priori to control for baseline values of the dependent variables, for which we used regression-based adjustments [38, 39] . The base case analysis considers the costs and benefits over the full trial period.
Both the incremental costs and incremental effects were used to calculate the incremental cost-effectiveness ratio (ICER). The ICER was calculated as (C intervention -C control group ) / (E intervention -E control group ), where "C" reflects the average participant costs and "E" are the effects or the utilities in the AIMS and TAU arms. The ICER represents the additional costs that AIMS imposes over TAU, with respect to the effects it delivers. To handle stochastic uncertainty in the cost and effect data, seemingly unrelated regression equations were bootstrapped (5000 times) to allow for correlated residuals of the cost and utility equations. The regression also adjusted for baseline log 10 viral load and patients' treatment experience (ie, treatment naive or experienced). The ICERs were plotted on a cost-effectiveness plane to capture the uncertainty in the ICER estimate.
The choice for a treatment depends on what society is prepared to pay for a gain in 1 QALY, the so-called ceiling ratio.
In the present study, we used an accepted Dutch threshold (for preventive interventions) of €18 000 per QALY [40] . The AIMS intervention was deemed to be cost-effective, if the ICER of AIMS fell below this threshold. Cost-effectiveness acceptability curves were constructed to show the probability that AIMS is cost-effective given different ceiling ratios. One patient reported an unrealistically high number of general practitioner (home) visits at baseline (z = 111.7); hence, this item was set to missing and imputed in the same way as all the other missing values.
The syntaxes and raw data are available at https://osf. io/2brxk/.
Sensitivity Analyses
We conducted several sensitivity analyses [41] . Two were conducted to address key limitations of the base-case analyses, that is, a high percentage of missing questionnaire data (ie, 50%) and variable recall periods for questionnaires at intermediate time points. A first sensitivity analysis used only the baseline and follow-up data (25% missing data and standardized recall period). A second sensitivity analysis examined whether individual means imputation provided similar results to expectation maximization [42] . This was done only for the cost-utility analyses as the viral load data were available for nearly all patients.
Additionally, we ran a sensitivity analysis that also considered the costs saved through reduced risk of HIV transmission. HIV transmission probabilities based on viral load data were provided by the lead author of an HIV transmission modeling study [10] , and multiplied by the lifetime costs for an HIV-infected patient [43] . Last, a sensitivity analysis adopting a healthcare perspective was performed (using direct costs only). This is the preferred perspective in some countries, utilizes mostly objective and complete data from medical databases, and is not influenced by a small number of patients in this trial reporting very high productivity losses.
RESULTS

Baseline Sample Characteristics
In total, 223 patients were randomized (intervention, n = 110; control group, n = 113; Table 1 ). Their mean age was 44 years Categorization was based on the Dutch education system as follows: low, less than primary education, primary education, lower secondary education; medium, higher secondary education, lower vocational education; high, higher vocational education, university.
(SD = 10.89), and most participants were male (84%) and white (65% Figure 1 . Consolidated Standards or Reporting Trials (CONSORT) diagram summarizing the progress of patients throughout the trial. The intention-to-treat sample comprised 2 patients who were excluded in the effectiveness analysis [28] . These 2 patients did not deliver any viral load data (and were therefore excluded in the effectiveness analysis), but they did complete questionnaires on healthcare consumption and utilities (and therefore included in the cost-effectiveness analyses). Abbreviations: AIMS, Adherence Improving Self-Management Strategy; HIV, human immunodeficiency virus; MEMS, Medication Event Monitoring System; TAU, treatment as usual.
Costs
The total intervention costs were €82.61 per patient (see Table 2 for Table 3 ).
Cost-effectiveness Analyses
During follow-up, the intervention and control group had a reduction of plasma log 10 viral load of 1.74 (SD, 1.75) and 1.34 (SD, 1.67), respectively. In terms of QALYs, the intervention group had an average utility of 0.908 (SD, 0.12) compared with 0.898 (SD,
8%] control patients).
ICERs were generated for log 10 viral load and treatment failure. Both ICERs showed that AIMS was slightly more expensive than TAU but also more effective, resulting in an ICER of €549 per reduction in log 10 viral load and €1659 per percentage decrease in treatment failure (Figure 2A and 2B) . The CEAC for log 10 viral load is shown in Figure 3A . If we are willing to pay €5000 or more for (on average) a point decrease in log 10 viral load, the probability that AIMS is cost-effective is 82%. The CEAC for treatment failure shows that the probability that AIMS is cost-effective from a societal perspective is 75% at a ceiling ratio of €10 000 or higher per percentage decrease in treatment failure ( Figure 3B ).
Cost-utility Analysis
An ICER was generated for the cost-utility base-case analysis (ie, including all time points), which showed that that AIMS resulted in higher costs compared to TAU but also in Based on the mean income in the Netherlands, corrected for age and gender.
more QALYs, giving an ICER of €27 759 per QALY gained ( Figure 2C ). The CEAC showed a 46%-55% probability that AIMS is cost-effective from a societal perspective for ceiling ratios ranging from €0 per QALY to €75 000 per QALY.
Sensitivity Analyses
The first sensitivity analysis, using only baseline and follow-up data, resulted in a dominant ICER (ie, AIMS was more effective and is cheaper than TAU). The CEAC showed a 72% to 74% probability that AIMS is cost-effective regardless of the ceiling ratios. The second sensitivity analysis using individual mean imputation showed similar results. The cost-effectiveness plane and CEACs for these analyses can be found in Supplementary Appendix 3. The third sensitivity analysis, which included the reduced risk of HIV transmission, showed lower costs and higher effects (ie, AIMS dominated TAU) for all outcomes ( Figure 2D-F) . Likewise, the analyses from a healthcare perspective produced dominant ICERs (Figure 2G-I ).
The percentages of bootstrapped ICERs that are covered for each quadrant of the cost-effectiveness plane are displayed in Figure 2D -I. The CEACs corresponding to each sensitivity analyses are provided in Figure 3D -I.
DISCUSSION
This multicenter randomized controlled trial investigated the cost-effectiveness and cost-utility of AIMS compared to TAU. AIMS resulted in a small gain in QALYs over the 15 months of follow-up, a decrease in viral load, and fewer patients with treatment failure. The probability that AIMS is cost-effective using plasma viral load as outcome parameter ultimately depends on the willingness to pay for a point decrease in plasma log 10 viral load or a treatment failure prevented. For cost-utility, the base case analysis produced an ICER above the willingness-to-pay threshold for preventive interventions in the Netherlands. This is unsurprising given the restricted follow-up period of 15 months. All sensitivity analyses, however, revealed considerably more favorable Figure 2 . Cost-effectiveness and cost-utility planes for the base cases (A-C) and 2 sensitivity analyses (D-F: including onward transmission; G-I: healthcare perspective), for log 10 viral load (column 1), treatment failure (column 2), and quality-adjusted life-years (column 3). Costs are in euros (€), based on the bootstrapped incremental cost-effectiveness ratios (5000 times). Abbreviations: pat., patients; prop, proportion; QALY, quality-adjusted life-years.
probabilities of AIMS being cost-effective. In particular, when using only baseline and follow-up data (less missing data and with standardized recall periods), adopting a healthcare perspective, or when accounting for HIV transmissions prevented, the analyses all suggest that AIMS is more effective and cheaper than TAU.
The current study is complementary to a recently published Markov model evaluating the cost-effectiveness of AIMS [28] . The Markov model was conducted to estimate the costs per QALY over longer follow-up periods (ie, 10 years and lifetime), and suggested that AIMS was dominant. The complementary value of the current trial-based economic evaluation is that it retains the integrity of randomization, it does not make assumptions about long-term effects as it utilizes observed data, and it includes short-term outcome measures (costs per viral load gain), which may be more directly relevant to clinicians. Combined, the trial-based and model-based analyses suggest that AIMS is likely cost-effective and potentially even cost-saving, regardless of the perspective.
It is challenging to compare the results of this trial with other proven cost-effective HIV treatment adherence interventions, as to our knowledge there has only been one previous cost-effectiveness analysis [44] . The authors of that study compared twice-weekly home visits with standard care, and concluded that this intervention was cost-effective using a model-based cost-effectiveness analysis. The quality of their economic evaluation was judged to be high in a systematic review [30] .
Limitations were that the authors did not describe the content of the intervention, the comparator, and that no evidence of effectiveness was provided. Our aim was to also conduct a high-quality evaluation by following the Drummond checklist [34] and guidelines for cost-effectiveness evaluations [45] . The AIMS intervention has been described in detail in previous publications and demonstrated reproducible effects on adherence and plasma viral load (Supplementary Appendix 4) . Moreover, the study was designed with a minimal risk of bias [31] , and the comparator arm receiving TAU was described in detail [2, 29, 33] .
Another strength of the current trial and economic evaluation is the heterogeneity of the study sample in terms of treatment experience, physical and mental comorbidities, educational level, and ethnicity; and that the intervention was delivered by HIV nurses working in academic and nonacademic settings, and with variable quality of TAU and nursing experience [33] . These characteristics suggest that the results may be generalizable to other settings in a similar (publicly funded) healthcare context. Transferability of costs to other healthcare systems cannot be guaranteed without careful consideration [46] . This study also had several limitations. First, part of our costs data relied on self-reports and although the questionnaire response rates (75%) were acceptable at baseline and follow-up, the nonresponse was a concern for the intermediate questionnaires (approximately 50% 
Willingness to pay (in €)
Willingness to pay (in €) W illingness to pay (in €) 0 5000 10 000 15 000 20 000 0 1 2 500 25 000 37 500 50 000 0 3 0 000 60 000 90 000 120 000 0 5000 10000 15 000 20 000 0 1 2 500 25 000 37 500 50 000 0 3 0 000 60 000 90 000 120 000 analyses suggest that this has resulted in a conservative estimate of cost-effectiveness in the base-case analysis. Second, the preplanned base case analyses did not incorporate the assumed reduction in forward transmission risk, but studies have now convincingly proven the societal impact (both in clinical and economic terms) of preventing onward transmission of HIV [10, 29] . It must be noted that the sensitivity analysis in which HIV transmission was included employs a relatively crude method for calculating transmission risk (ie, a cumulative probability rather than a dynamic transmission model). Finally, we used the observed viral loads as input in this study. These are slightly different from those used in the Markov model, which used relative risks estimated from a model that adjusted for additional covariates [29] .
In conclusion, the primary analysis suggests that AIMS is more costly but also more effective, and may possess a favorable profile in terms of cost-effectiveness (costs per viral load gain) and cost-utility (costs per QALY). Sensitivity analyses designed to address missing data limitations in the base case produced more favorable cost-utility probabilities for AIMS. Additional sensitivity analyses showed that when onward viral transmission is considered or a healthcare perspective is adopted, AIMS is cheaper and more effective than TAU (ie, dominant) in all scenarios. The current trial-based economic evaluation complements the model-based economic evaluation with a longer horizon, showing that AIMS is cost-effective. Combined, these studies suggest that incorporating AIMS in routine HIV care could lead to relevant benefits for only a modest investment.
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